Levi A Garraway

US Patent:

8637246, Jan 28, 2014

Filed:

Feb 22, 2011

Appl. No.:

13/580651

Inventors:

Levi Garraway - Newton MA, US
Caroline Emery - Brookline MA, US

Assignee:

Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12Q 1/00
A61P 35/00

US Classification:

435 611, 514 193

Abstract:

The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of BRAF. In particular embodiments, the invention concerns mutations in a BRAF sequence that confer resistance to a BRAF inhibitor. Identification of such mutations in a BRAF sequence allows the identification and design of second-generation BRAF inhibitors. Methods and kits for detecting the presence of a mutant BRAF sequence in a sample are also provided.

US Patent:

20090004652, Jan 1, 2009

Filed:

Jun 8, 2007

Appl. No.:

11/811149

Inventors:

Mark A. Rubin - Cambridge MA, US
Francesca Demichelis - Cambridge MA, US
Levi A. Garraway - Newton MA, US
William R. Sellers - Brookline MA, US

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

Described are methods for identifying single nucleotide polymorphism (SNPs) that are useful for analyzing genetic samples, and for using said SNPs to determine genetic identity of samples.

US Patent:

20120015973, Jan 19, 2012

Filed:

Dec 10, 2009

Appl. No.:

13/139060

Inventors:

Levi A. Garraway - Newton MA, US
Caroline Emery - Brookline MA, US
Carlos Garcia Echeverria - Basel, CH

Assignee:

Novartis AG - Basel
Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

A61K 31/437
C12N 15/63
C12N 9/12
A61P 35/02
C12N 1/21
C12N 5/10
A61P 35/00
C12N 15/54
C12Q 1/68

US Classification:

514300, 536 232, 4353201, 435194, 435 612, 4352523, 43525233, 435325, 435369

Abstract:

The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of MEK. In particular embodiments, the invention concerns mutations in a MEK sequence that confer resistance to a MEK inhibitor. Identification of such mutations in a MEK sequence allows the identification and design of second-generation MEK inhibitors. Methods and kits for detecting the presence of a mutant MEK sequence in a sample are also provided.

US Patent:

20130059851, Mar 7, 2013

Filed:

Mar 9, 2011

Appl. No.:

13/583056

Inventors:

Levi A. Garraway - Newton MA, US
Cory M. Johannessen - Roslindale MA, US

Assignee:

DANA-FARBER CANCER INSTITUTE, INC. - Boston MA

International Classification:

A61K 31/437
C40B 30/04
G01N 33/574
C40B 30/06
A61K 31/4439
A61P 35/00
A61K 31/444
A61K 31/167
A61K 31/166
A61K 31/353
A61K 31/5377
A61K 31/18
C12Q 1/68
A61K 31/44

US Classification:

5142352, 435 611, 506 9, 435 792, 435 74, 506 10, 514338, 514346, 514341, 514300, 514619, 514394, 514456, 5142362, 514605

Abstract:

A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a RAF inhibitor and a second inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a RAF inhibitor and an effective amount of a second inhibitor, wherein the second inhibitor is a MEK inhibitor, a CRAF inhibitor, a CrkL inhibitor or a TPL2/COT inhibitor. A method of identifying a kinase target that confers resistance to a first inhibitor is also provided.

US Patent:

20130143911, Jun 6, 2013

Filed:

Jun 9, 2011

Appl. No.:

13/701889

Inventors:

Levi A. Garraway - Newton MA, US
Caroline Emery - Brighton MA, US
Nikhil Wagle - Brookline MA, US

Assignee:

Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

A61K 31/4745
C07H 21/04
C12N 9/12
C12Q 1/68

US Classification:

514300, 536 232, 4353201, 4352523, 435194, 435 612, 43525233, 435366, 514394

Abstract:

Nucleic acids and proteins having a mutant MEK sequence, and methods concerning identification of patients having resistance to treatment with anti-cancer agents, specifically inhibitors of RAF or MEK are provided. Methods of treatment and for optimizing treatment for patients having a mutation in a MEK1 sequence are also provided.

US Patent:

20130171124, Jul 4, 2013

Filed:

Jul 25, 2012

Appl. No.:

13/557988

Inventors:

Le Cong - Brookline MA, US
Ann Marie Egloff - Pittsburgh PA, US
Levi A. Garraway - Newton MA, US
Jennifer Rubin Grandis - Pittsburgh PA, US
Eric S. Lander - Cambridge MA, US
Nicholas Stransky - Boston MA, US
Aaron D. Tward - Boston MA, US
Feng Zhang - Cambridge MA, US

International Classification:

A61K 38/16
A61K 45/06
A61K 38/46

US Classification:

424 946, 514 193, 435375

Abstract:

The present invention provides methods related to the treatment of head and neck squamous cell carcinoma (HNSCC) and its associated premalignant lesions. In particular, the invention features methods which may specifically target HNSCC-associated genes and alter gene expression to treat or alleviate a symptom of HNSCC, or its related premalignant lesions. These methods may involve decreasing the function of an HNSCC-associated gene with aberrant gain-of-function; or increasing the function of an HNSCC-associated gene with aberrant loss-of-function.

US Patent:

20210388325, Dec 16, 2021

Filed:

Aug 11, 2021

Appl. No.:

17/399563

Inventors:

- Boston MA, US
Rajee Antony - Norwood MA, US
Levi A. Garraway - Newton MA, US

Assignee:

DANA-FARBER CANCER INSTITUTE, INC. - Boston MA

International Classification:

C12N 9/12
C12Q 1/6886

Abstract:

Nucleic acids and proteins having a mutant C-RAF sequence, and methods of identifying patients having cancer who are likely to benefit from a combination therapy and methods of treatment are provided.

US Patent:

20210277482, Sep 9, 2021

Filed:

Mar 16, 2021

Appl. No.:

17/203674

Inventors:

- Cambridge MA, US
- Boston MA, US
Levi A. Garraway - Newton MA, US

Assignee:

The Broad Institute, Inc. - Cambridge MA
Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12Q 1/6886
G01N 33/574
A61K 31/437

Abstract:

The invention provides methods and devices for determining molecular signatures in a cancer that predict response to a MARPK pathway inhibitor and methods of use of such signatures.